VBIT-4 & VBIT-12: the molecules trying to stop VDAC1 from ganging up

If you've read my VDAC1 primer, you know the villain isn't VDAC1 doing its normal job — it's VDAC1 oligomerizing, clumping into a big pore that leaks cytochrome c and mtDNA and kicks off cell death plus inflammation. So the obvious question: can we block the clumping without breaking the gate?

That's exactly what the VBIT compounds are built to do. This is my running, plain-language summary of where that story stands.

Where the idea came from

It got a huge boost from a 2019 paper in Science (Kim et al.) that I think is genuinely a landmark. The team showed VDAC1 oligomers form pores that release mtDNA fragments, and that this drives a lupus-like autoimmune disease in mice. Crucially, treating with VBIT-4 reduced the mtDNA release and calmed the disease down.

Stop the pore from forming, and you can turn down the downstream damage — in a living animal, not just a dish.

That's the proof-of-concept the whole field leans on. The paper and follow-ups are on my resources page.

What VBIT-4 and VBIT-12 actually do

Both are small molecules that bind VDAC1 and prevent it from oligomerizing. The intent is selective: leave single-channel traffic mostly intact, but block the pathological grouping-up. VBIT-12 is generally the more potent sibling. The chain they interrupt runs stress → oligomerization → big pore → cytochrome c + mtDNA leak → apoptosis + cGAS–STING inflammation. VBIT compounds aim at the earliest step — which is exactly what a 2026 T-cell paper saw when VBIT-12 shut down mtDNA-driven inflammation.

Where they've been tested

Since the lupus paper, VDAC1-oligomerization inhibitors have been poked at across a surprisingly wide spread of preclinical models — autoimmune/inflammatory disease, fatty liver and metabolic disease, kidney injury, cardiac stress, and neurodegeneration. I keep the current links on the resource shelf, because this part moves.

The honest caveats

I get excited about this, so I try hard to stay sober. This is preclinical — most of the exciting data is cells and mice, and the graveyard of drug development is full of molecules that looked great in mice. Selectivity is everything: VDAC1 does essential normal jobs, and a drug that also gums up normal traffic could cause the very harm you're trying to prevent. "Involved in" isn't "the cause of." And delivery to the brain is its own mountain.